Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

(2015) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes

(2015) Yuichiro Otsuka et al.   ENDOCRINE JOURNAL

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin—The Sit2Mix trial

(2015) Sultan Linjawi et al.   Primary Care Diabetes

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

(2015) Chantal Mathieu et al.   Diabetes Therapy

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

(2015) Chantal Mathieu et al.   Diabetes Therapy

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

(2014) Bruce Neal et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

(2014) A. Avogaro et al.   DIABETES OBESITY & METABOLISM

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

(2014) J. Farngren et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase

(2014) Kohei Kaku et al.   EXPERT OPINION ON PHARMACOTHERAPY

The durability of sitagliptin in elderly patients with type 2 diabetes

(2014) Ching Jung Hsieh et al.   Clinical Interventions in Aging

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy

(2013) Anthony H. Barnett et al.   CLINICAL DRUG INVESTIGATION

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study

(2013) H. Yki-Jarvinen et al.   DIABETES CARE

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

(2012) Anthony H. Barnett et al.   CURRENT MEDICAL RESEARCH AND OPINION

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study

(2012) E. S. Hong et al.   DIABETES OBESITY & METABOLISM

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

(2012) D. Devineni et al.   DIABETES OBESITY & METABOLISM

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

(2012) Johan Farngren et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

The effects of glucagon-like peptide-1 on the beta cell

(2009) T. Vilsbøll   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM